Side Effects | Duration of Deprivation | Percent Change or Hazard Ratio |
---|---|---|
Bone mineral density and fracture risk | ||
Bone mineral density | 6 months | −3.5%17 |
12 months | −5.3%15 | |
12 months | −3.3%16 | |
12 months | −4.9% and −6.8%4 | |
Any fracture* | 5 years | 1.45 (95% CI: 1.36–1.56)21 |
Fracture resulting in hospitalization* | 5 years | 1.66 (95% CI: 1.47–1.87)21 |
Glucose and lipid metabolism | ||
Weight and body mass index | 6 months | +0.8%17 |
11 months | +2.4%23 | |
Fat body mass | 3 months | +8.4%18 |
11 months | +9.4%23 | |
Lean body mass | 3 months | −2.8%18 |
11 months | −2.7%23 | |
Muscle area | 11 months | −3.2%23 |
Total cholesterol level | 6 months | +6.1%17 |
11 months | +9.0%23 | |
High-density lipoproteins cholesterol level | 11 months | −11.3%23 |
Low-density lipoproteins cholesterol level | 11 months | +7.3%23 |
Triglyceride level | 6 months | +8.2%17 |
11 months | +27%23 | |
Fasting insulin level | 3 months | +64%18 |
Incident diabetes | 4.6 years | 1.44 (95% CI: 1.34–1.55)32 |
Incident coronary heart disease | 4.6 years | 1.16 (95% CI: 1.10–1.21)32 |
Incident myocardial infarction | 4.6 years | 1.11 (95% CI: 1.01–1.21)32 |
Incident sudden cardiac death | 4.6 years | 1.16 (95% CI: 1.05–1.27)32 |
Mood disturbances | ||
Depression (or other affective disorder) | 4.3 years | 1.08 (95% CI: 1.02–1.15)49 |
Constitutional symptoms (e.g., fatigue, malaise, anorexia, abnormal weight gain, debility) | 4.3 years | 1.17 (95% CI: 1.13–1.22)49 |
* Among those receiving nine or more doses of gonadotropin-releasing hormone agonist in the first 12 months after diagnosis of prostate cancer.